Brainstorm Cell Therapeutics Secures $1M Financing for ALS Phase IIIb Trial

Brainstorm Cell Therapeutics Inc. announced it has entered into a definitive agreement for a strategic private placement of $1 million. The financing was structured to reflect the company's current operational momentum and the underlying value of its NurOwn platform.

The common stock was priced at $0.60 per share, representing a significant premium to the $0.54 closing price on Monday, February 9, 2026, the date the transaction was finalized. The investment includes 120% warrant coverage for five years with an exercise price of $1.00 per share. This strike price represents a nearly 100% premium to the recent market close.

The financing is being completed in two tranches, with the first payment of $500,000 already received and the final payment of $500,000 scheduled for receipt within 30 days. The Company must file a registration statement registering the resale of the common stock and warrants within 45 days.

Proceeds from the financing will be used to support ongoing regulatory initiatives, prepayments for the upcoming Phase 3b trial of NurOwn in ALS, and general corporate purposes. The financing will support an upcoming Phase IIIb trial of its stem cell therapy for amyotrophic lateral sclerosis.

The financing follows a period of intense strategic activity for BrainStorm, as the company finalizes its Phase 3b trial design under a Special Protocol Assessment (SPA) and engages in high-level discussions regarding the pending Citizens Petition for Accelerated Approval. The company filed a Form 8-K regarding this transaction with the Securities and Exchange Commission on Friday, February 13, 2026.

The NurOwn technology platform (autologous MSC-NTF cells) represents a promising investigational therapeutic approach to targeting disease pathways important in neurodegenerative disorders. MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo. MSCs are converted into MSC-NTF cells by growing them under patented conditions that induce the cells to secrete high levels of neurotrophic factors (NTFs).

NurOwn is BrainStorm's lead investigational therapy for amyotrophic lateral sclerosis (ALS) and has received Orphan Drug designation from both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). A Phase 3 trial in ALS (NCT03280056) has been completed, and a second Phase 3b trial is set to launch under a Special Protocol Assessment (SPA) agreement with the FDA.